Anebulo Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $-8.5M | $-8.2M | $-11.7M | $-6.8M | $-30.3M |
| Depreciation & Amortization | — | — | — | — | — |
| Depreciation | — | — | — | — | — |
| Amortization | — | — | — | — | — |
| Stock-Based Compensation | $1.4M | $758.9K | $884.7K | $480.7K | $199.9K |
| Net Cash from Operating Activities | $-6.3M | $-8.1M | $-9.7M | $-5.4M | $-4.9M |
| Investing Activities | |||||
| Capital Expenditures | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | — |
| Financing Activities | |||||
| Dividends Paid | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — |
| Net Cash from Financing Activities | $14.9M | $-62.4K | $6.4M | — | $21.8M |
| Net Change in Cash | $8.5M | $-8.2M | $-3.3M | $-5.4M | $17.0M |
| Free Cash Flow | — | — | — | — | — |